Sigachi Industries Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tyb7o4hbvvvh3cn56of96ulh.pdf

Key Takeaways


Revenue & Realization Drivers

Amit Raj Sinha: "I am sure you would believe that currently the prices are most of the prices are already at its peak. So, we do not see further price being going up. However, in case there is significant change in the crude oil or in the raw material prices we would not really hesitate in passing on the price."

Margin Structure & Cost Trends

Amit Raj Sinha: "I am very comfortable or very confident on maintaining our margins even if the realizations drop the comfort and confident of maintaining our margins remains intact. ... if I have been higher than 20% EBITDA I would continue to see that I am a 20%, 21% EBITDA all throughout irrespective of our decrease in our realization or increase in our realizations."

Capacity Expansion & Utilization

Amit Raj Sinha: "At this moment our focus is to see that the execution of the CAPEX gets done as fast as possible. ... in terms of utilizing of all this added capacity over two years we still stand by it, but is very difficult to give a firm commitment on this because there is outside situation, there are lot of other variables which come in. ... maybe the two years might change to three-year period, but on a positive note I believe that we should be able to absorb a major chunk of the added capacity over the next two years."

Diversification Bets: Nutraceuticals, CCS & Healthcare

Amit Raj Sinha: "EC clearance expected timelines anything what we speak is we cannot be very sure, but I personally expect that it should get on an earlier note, it should get done within 6 months, if it is get on a delayed note it might get done within 12 months."

O&M Business & Strategic Positioning

Amit Raj Sinha: "I am actually very bullish on the O&M part of our business. One of the prime reasons is that it does not involve the CAPEX. It is a service industry and in the service industry I can show my results upfront."

Guidance & Commitments

CommitmentSpecificsTimeline
New MCC capacity commissioning7,000 MT brownfield expansion at Dahej and Jhagadia ready; commissioning activity to commenceQ4 FY23
New MCC capacity first salesSales from new capacity to start showingQ1 FY24
New MCC capacity absorption~70–80% utilization of expanded capacityOver next two years (could extend to three)
First-year utilization of new MCC capacity~30% utilizationFirst year post-commissioning
Nutraceutical revenue₹12–15 CrH2 FY23
CCS plant EC clearanceEnvironmental clearance for croscarmellose sodium plant6–12 months
CCS plant commercializationRevenue to begin post 15–18 month lead time after EC clearanceNext financial year (FY24)
Tax rate18–20% guided rateFY23
Lower tax rate duration11% rate from deferred tax assets continuesAnother 4 years until SEZ exemption lapses
Depreciation run-rate~₹2.1 Cr quarterlyAt least through H2 FY23 until new plant operational
EBITDA margin floorAbove 20–21% irrespective of realization changesOngoing
Q3 price increaseSingle-digit price rise for some customersQ3 FY23
Post-expansion debottleneckingAdditional 25% capacity on expanded baseOver a period of time, not immediately

Key Metrics

MetricQ2 FY23
Operational income₹83 cr, +44.2% YoY
EBITDA₹16 cr, +~21% YoY
EBITDA margin19.76%
Net profit after tax₹14 cr, +37.4% YoY
PAT margin16.48%, -82 bps YoY
Volume growth~8.5% YoY
Realization growth25% YoY
Sales volume~3,500 metric tons
Capacity utilization94.5%
Export sales (H1 FY23)₹113.2 cr, +40% vs ₹80.87 cr in H1 FY22
Raw material cost$900–$950, vs ~$850 in Q1 and ~$650 YoY
Average selling price₹217.04, vs ₹216.75 in Q1
O&M revenue (FY23 expectation)~₹25 cr, vs ₹13.5 cr in FY22
O&M EBITDA margin~22%
Nutraceutical revenue (H1 FY23)Less than ₹1 cr
Nutraceutical revenue (FY23 guidance)₹12–15 cr, revised from ₹18–20 cr